Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833208 · ClinicalTrials.gov registry record · NA
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT01833208 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT01833208, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This pilot clinical trial studies the impact of radiation therapy on the immunogenicity of Sipuleucel-T. Patients with castration recurrent prostate cancer who are eligible for treatment with Sipuleucel-T and who have bone metastases are eligible.
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2013-07-03 |
| Est. Completion | 2021-01-23 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01833208
The ClinicalTrials.gov registry entry for NCT01833208 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01833208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01833208 about?
NCT01833208 is a clinical study titled "Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T". This pilot clinical trial studies the impact of radiation therapy on the immunogenicity of Sipuleucel-T. Patients with castration recurrent prostate cancer who are eligible for treatment with Sipuleucel-T and who have bone metastases are eligible.
What is the current status of trial NCT01833208?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2013-07-03. Estimated completion is 2021-01-23.
What interventions are being tested in trial NCT01833208?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01833208?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.